Report: FDA's Office of Generic Drugs takes medical leave

WASHINGTON — Thirty-year Food and Drug Administration veteran Kathleen “Cook” Uhl, who was appointed director of the FDA’s Office of Generic Drugs in January, is temporarily stepping down to deal with a medical issue, according to a report by the Regulatory Focus Professionals Society.



Uhl is reportedly being treated for colorectal cancer and will be on leave for several months.



While Uhl is out, John Peters, acting director of the Office of Bioequivalence, will lead the OGD on an acting basis, according to the report. Dale Connor will become acting director of the Office of Bioequivalence.